These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 10506721)

  • 41. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
    Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
    Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study.
    Hussain MH; Glass TR; Forman J; Sakr W; Smith DC; Al-Sarraf M; Jones J; Balcerzak SP; Crawford ED; Grossman HB
    J Urol; 2001 Jan; 165(1):56-60; discussion 60-1. PubMed ID: 11125363
    [TBL] [Abstract][Full Text] [Related]  

  • 43. M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen.
    Igawa M; Kadena H; Ueda M; Usui T
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S1-4. PubMed ID: 7527732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
    Jiang Y; Qiu XH; Yang YX; Zhang SQ; Chen ZM
    Ai Zheng; 2006 Aug; 25(8):1029-34. PubMed ID: 16965688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
    Lin CC; Hsu CH; Huang CY; Tsai YC; Huang KH; Cheng AL; Pu YS
    Urology; 2007 Mar; 69(3):479-84. PubMed ID: 17382149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemotherapy with methotrexate, carboplatin, mitoxantrone (Novantrone) and vincristine (Oncovin) in transitional-cell urothelial cancer.
    Pectasides D; Mylonakis A; Antoniou F; Kostopoulou M; Triantaphyllis D; Papadopoulou M; Varthalitis J; Dimitriadis M; Athanassiou A
    Oncology; 1998; 55(2):139-44. PubMed ID: 9499188
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation.
    Edelman MJ; Meyers FJ; Miller TR; Williams SG; Gandour-Edwards R; deVere White RW
    Urology; 2000 Apr; 55(4):521-5. PubMed ID: 10736495
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract.
    Hillcoat BL; Raghavan D; Matthews J; Kefford R; Yuen K; Woods R; Olver I; Bishop J; Pearson B; Coorey G
    J Clin Oncol; 1989 Jun; 7(6):706-9. PubMed ID: 2654329
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
    Droller MJ
    J Urol; 2000 May; 163(5):1601. PubMed ID: 10798920
    [No Abstract]   [Full Text] [Related]  

  • 51. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
    Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
    Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer].
    Taïeb J; Lecomte T; Ezenfis J; Artru P; Mitry E; Boige V; Clavero-Fabri MC; Vaillant JN; Rougier P; Ducreux M
    Gastroenterol Clin Biol; 2002; 26(6-7):605-9. PubMed ID: 12193860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
    Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type.
    Taamma A; Fandi A; Azli N; Wibault P; Chouaki N; Hasbini A; Couteau C; Armand JP; Cvitkovic E
    Cancer; 1999 Oct; 86(7):1101-8. PubMed ID: 10506692
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
    Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
    Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II study of a new combined primary chemotherapy regimen, intravenous methotrexate and vincristine and intraarterial adriamycin and cisplatin, for locally advanced urinary bladder cancer: preliminary results.
    Kuroiwa T; Naito S; Hasuo K; Kishikawa T; Masuda K; Kumazawa J
    Cancer Chemother Pharmacol; 1995; 35(5):357-63. PubMed ID: 7850915
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17).
    Choi YJ; Lee SH; Lee JL; Ahn JH; Lee KH; You D; Hong B; Hong JH; Ahn H
    Br J Cancer; 2015 Jan; 112(2):260-5. PubMed ID: 25429526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.